De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von ChunMei An und 12 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China. Hauptthemen laut MEDLINE: Interleukin-11, Drug Discovery, Kidney, Kidney Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Jiangsu Provincial Department of Education, Taishan Scholar Project of Shandong Province.
Abstract (Originalsprache)
Emerging evidence has highlighted the pathological involvement of interleukin-11 (IL-11) in fibrotic disorders. In this study, we identified a novel peptide antagonist 4L2 through the random nonstandard peptide integrated discovery (RaPID) system, which exhibits a high binding toward IL-11, with a KD value of 5.26 nM. Additionally, cell-based assays revealed that 4L2 displays a moderate antagonistic activity, with an IC50 value of 22.7 ± 1.9 μM. Through performing alanine scanning and subsequent structural optimization, we developed an improved variant, 4L2-P13D, which showed significantly enhanced antagonistic activity, with an IC50 value of 2.8 ± 0.5 μM. Furthermore, 4L2-P13D demonstrated the significant renoprotective effects in in vitro and in vivo models. These findings indicate that the analogue 4L2-P13D represents a promising lead candidate for developing targeted IL-11 therapeutics against renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao, Shandong 266237, China.
- Shandong Research Institute of Industrial Technology, Jinan, Shandong 250101, China.
ORCID-Profile: Dong Guo, Yizhen Yin, Xiaochun Xiong
Förderung
- National Key Research and Development Program of China
- Jiangsu Provincial Department of Education
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Scientific Research Foundation for Talented Scholars in Xuzhou Medical University
- Scientific Research Foundation for Talented Scholars in the Affiliated Hospital of Xuzhou Medical University
Zitieren
APA
An, C., Cai, W., Li, P., Li, J., Zhao, N., Yang, X., Li, K., Pang, N., Cheng, X., Wang, N., Guo, D., Yin, Y., & Xiong, X. (2025). De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01432
Vancouver
An C, Cai W, Li P, Li J, Zhao N, Yang X, et al. De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01432
BibTeX
@article{An2025,
author = {An, ChunMei and Cai, Wenfeng and Li, Peiying and Li, Jian and Zhao, Na and Yang, Xu and Li, Keqiang and Pang, Ningning and Cheng, Xing and Wang, Naiyuan and Guo, Dong and Yin, Yizhen and Xiong, Xiaochun},
title = {De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01432}
}
EUVIMED